Inclusion Criteria:

- Documented acute lymphoblastic leukemia (L1 or L2 subtypes)

- First or subsequent relapse

- 365 days of age or older

- Greater than 7 days from any chemotherapy or immunotherapy, with the exception of
intrathecal chemotherapy

- Absolute peripheral leukemia blast count of 1000 cells/ul or greater

- Patient (or parent/guardian if patient is less than 18 years of age) must sign
informed consent

Exclusion Criteria:

- Burkitts leukemia (acute lymphoblastic leukemia L3 subtype)

- Uncontrolled active infection

- Pregnancy or mothers who are nursing

- Patient currently taking rapamycin

- Patients with significant liver dysfunction as outlined in protocol

- Severe concurrent disease, which in the judgment of the investigator, would make the
patient inappropriate for entry into the study

- Active psychiatric disease, substance abuse, or mental illness that would interfere
with cooperation with the requirements of the trial